mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.016 |
0.6 |
mRNA |
Nilotinib |
CTRPv2 |
pan-cancer |
AAC |
0.019 |
0.6 |
mRNA |
navitoclax:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.017 |
0.6 |
mRNA |
EX-527 |
GDSC1000 |
pan-cancer |
AAC |
0.017 |
0.6 |
mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.017 |
0.6 |
mRNA |
rigosertib |
CTRPv2 |
pan-cancer |
AAC |
0.016 |
0.6 |
mRNA |
Bexarotene |
CTRPv2 |
pan-cancer |
AAC |
0.018 |
0.6 |
mRNA |
BRD-K48334597 |
CTRPv2 |
pan-cancer |
AAC |
0.033 |
0.6 |
mRNA |
BRD-K19103580 |
CTRPv2 |
pan-cancer |
AAC |
-0.018 |
0.6 |
mRNA |
VER-155008 |
CTRPv2 |
pan-cancer |
AAC |
-0.018 |
0.6 |